Search Results - paul+robbins

11 Results Sort By:
Machine Learning Model for the Prioritization of Cancer Neoepitopes
Summary: The National Cancer Institute (NCI) seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy. Description of Technology: Success in immunotherapy is often attributable to the reactivity of patient T-cells to specific mutated peptide(s) found...
Published: 4/16/2026   |   Updated: 11/29/2024   |   Inventor(s): Jared Gartner, Paul Robbins, Steven Rosenberg
Keywords(s):  
Category(s): Application > Research Materials, TherapeuticArea > Oncology, Collaboration Sought > Licensing
T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary: The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations. Description of Technology: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery
Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
Summary: NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs. Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy
Abstract: The tumor protein p53 is a cell cycle regulator. It responds to DNA damage by triggering the DNA repair pathway and allowing cell division to occur or inducing cell growth arrest, cellular senescence, and/or apoptosis. p53 therefore acts as a tumor suppressor by preventing uncontrolled cell division. However, mutations in p53 that impair...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Drew Deniger, Parisa Malekzadeh, Winifred Lo, Rami Yoseph, Paul Robbins, Maria Parkhurst, Anna Pasetto, Yong-Chen Lu, Steven Rosenberg
Keywords(s): Immunotherapy, p53, Rosenberg, T Cell Receptor, TCR, Tumor Protein P53
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer
Abstract: Vaccines against non-viral cancers target mainly differentiation antigens, cancer testis antigens, and overexpressed antigens.  One common feature to these antigens is their presence in central immunological tolerance. Using these vaccines, T cells underwent depletion of high avidity clones directed against such antigens. This depletion can...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Gal Cafri, Paul Robbins, Jared Gartner, Steven Rosenberg
Keywords(s): CANCER, Dendritic cells, Immunotherapy, Neoantigens, Rosenberg, T Cells, vaccines
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines
T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy
Abstract: Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors. Point mutations in the KRAS gene most frequently affect amino acid position 12, resulting in the substitution of the native glycine (G) residue for other amino...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Eric Tran, Yong-Chen Lu, Paul Robbins, Steven Rosenberg, Anna Pasetto, Zhili Zheng
Keywords(s): CANCER, Immunotherapy, Mutated KRAS, Rosenberg, T-cell Receptors
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
T-Cell Therapy Against Patient-Specific Cancer Mutations
Description of Technology: Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets. Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Eric Tran, Yong-Chen Lu, Paul Robbins, Steven Rosenberg
Keywords(s): Cholangiocarcinoma, Immunogenic, Rosenberg, T-cell, Tran
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients
Summary: NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL). Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg
Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation
Summary: The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation. Description of Technology: Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Paul Robbins, Steven Rosenberg, Gabriel Ivey, Almin Latani
Keywords(s): act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing
T-Cell Therapy Against Patient-Specific Cancer Mutations
Abstract: Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets. Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize immunogenic mutations...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Eric Tran, Paul Robbins, Yong-Chen Lu, Steven Rosenberg
Keywords(s): Cholangiocarcinoma, Immunogenic, T cell, T-cell
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
1 2